.

Layne Smith structures and negotiates mergers, acquisitions, joint ventures and other transactions for strategic buyers, private company sellers, private equity sponsors, and healthcare operators—turning complex deals into closed transactions.

Whether representing a hospital system in executing a roll-up of surgery centers and medical practices, a founder-owned business in an exit transaction involving a private equity buyer, or a family office forming a joint venture, Layne structures transactions from letter of intent through closing with a focus on protecting his clients' economic interests and managing deal risk.

Layne's deepest industry concentration is healthcare mergers and acquisitions. He regularly advises hospitals, surgical centers, physician practices, and healthcare investors on the full range of M&A activity—acquisitions, divestitures, minority investments, and joint ventures. He also serves as outside general counsel for healthcare operators, negotiating service agreements, lease agreements, and supporting regulatory compliance on an ongoing basis.

Beyond healthcare, Layne advises clients across a range of M&A and corporate transactions in technology, software, real estate, manufacturing, and financial services. His M&A work spans both buy-side and sell-side mandates, and he regularly negotiates purchase agreements, operating agreements, services agreements, and development agreements on behalf of buyers, sellers, and investors alike.

Layne is ranked by Chambers USA and, according to his clients, he is “exceptional” and “a fantastic external resource with a keen legal mind and ability to deliver consistent results.” He is a committed user of AI tools in his practice and integrates them to deliver more efficient and precise work product for clients.

Select Experience

  • Represented a hospital system in the sale of a $125 million minority interest to a strategic investor.
  • Represented a hospital in the acquisition of dozens of health care facilities, including ambulatory surgical centers, urgent care facilities, and physician practices.
  • Represented a healthcare business in a $380 million preferred equity repurchase and restructuring.
  • Represented Agent Boost Marketing in its sale to AmeriLife.

Education

  • Brigham Young University (J.D., 2005)
    • magna cum laude
  • Brigham Young University (B.A., 2001)
    • cum laude

Bar Admissions

  • Utah

Court Admissions

  • U.S. Court of Appeal for the Tenth Circuit
  • U.S. District Court for the District of Utah

Professional Affiliations

  • Board of Directors, Camp Kostopulos Dream Foundation, 2014-2020     
  • Alumni Board, BYU Law School,  2008-2015
  • Board of Directors, The Living Planet Aquarium, 2007-2010

Accolades

  • Chambers USA, Corporate/M&A, Utah, 2023-2026
  • Best Lawyers in America®, 2021-2026
  • Legal 500, Mergers & Acquisitions, 2015, 2019
  • Utah Business Magazine Legal Elite, Corporate Law and Transactions; Mergers and Acquisitions, 2013, 2015-2020
  • American College of Trust & Estate Counsel, First Place, Mary Moers Wenig Student Writing Competition, 2005
  • J. Reuben Clark Law School, Faculty Award for Meritorious Achievement and Distinguished Service, 2005
  • J. Reuben Clark Law School, J. Reuben Clark Award, 2004

Select Presentations

  • The Case of Disney’s Abandoned Fusion Joint Venture – Planning for an Exit, Association of Corporate Counsel Seminar (August 31, 2016)

Insights

Media Mentions

Utah 2023 Legal Elite

June 1, 2023

Articles

Chemical Industry Update - January 2020

January 17, 2020

Antitrust Liability Allocation and the Problem of “Oversharing” As with other mature industries, many sectors of the chemical industry have become relatively concentrated over the years. Under these circumstances, current U.S. antitrust laws often create perverse incentives that lead to significant exposure for industry defendants, even where violations are de minimis or non-existent. With antitrust reform being much in the air of late, some modest changes to how liability is apportioned among defendants would seem in order to both improve the level of fairness overall and encourage new entrants by removing barriers to entry. In any federal civil antitrust case, private antitrust damages awarded by a jury are automatically trebled. And, in a case with more than one defendant, liability is “joint and several”—meaning that a successful plaintiff can recover three times the amount of harm it suffered as a result of anticompetitive activity, and it may recover that amount from any non-settling defendant it chooses, regardless of that defendant’s market share or relative degree of responsibility for the alleged conspiracy. This means that each defendant faces potential liability of three times the industry-wide damages that the antitrust violation allegedly caused. This is of particular note in industries, including the chemicals industry, that are relatively concentrated and are therefore likely to see greater antitrust scrutiny. Two features of the antitrust liability allocation rules mean that a defendant cannot shift any of its liability to other defendants that may be more culpable. First, a defendant has no right to make its co-defendants pay their fair share—that is, no right of “contribution.” That distinguishes antitrust from other types of cases, where a defendant that loses a trial can typically at least avoid paying a disproportionate share by claiming contribution from those defendants that it can show are more culpable. Second, when a case is tried to judgment, a settlement reached earlier in the case with one defendant is deducted from the trebled damages, not from the actual damages—and without regard to the relative share of damages for which the settling defendant ought to be responsible. In other words, there is no right of claim reduction proportionate to settling defendants’ share of liability. Together, these two allocation rules contribute to a race for even innocent or mostly innocent defendants to settle early, leaving the remaining defendants on the hook for an unfairly large share of damages. As a result, a company named as a defendant in any kind of antitrust conspiracy case has no good choices: it can either pay a substantial amount of money to settle the claims, or it can take on the risk that it may ultimately be held responsible for paying three times the actual damages caused by the conspiracy, reduced only by the actual amount of any settlements by other defendants. If the company has actually participated in the conspiracy, then those choices may be fair enough (and in those circumstances, companies may try to negotiate “judgment sharing” agreements with their co-defendants). But even if the company concludes, after a thorough self-investigation, that it has done nothing wrong, the choices remain the same. That is true even if the company has a relatively small market share or participated in the alleged conspiracy for only a short period of time (or believes it did not do so at all). There may be some appetite for reform. After all, the bipartisan Antitrust Modernization Commission recommended in 2007 that the federal antitrust laws be amended both to allow for a right of contribution among non-settling defendants and also to permit non-settling defendants to obtain reduction of a plaintiff’s claims by the amount of any settlements or the allocated share(s) of liability of settling defendants, whichever is greater. And antitrust has already received more attention in the current campaign for the Democratic nomination for the presidency than in any national election in decades. Perhaps addressing these damages-allocation rules could form part of a bipartisan reform package. But for the time being, even a company that is completely innocent or that at worst played a minor role in an anticompetitive agreement may reasonably feel compelled to rush into settlement for fear of being left exposed to pay industry-wide damages that are disproportionate to the company’s responsibility. For more information, contact Michael Lindsay and Anthony Badaracco. NOTES FROM ALL OVER General Counsel Faces Prospect of Duty of Care Violations for SEC Disclosure Violations. A recent Delaware motion to dismiss ruling leaves a company’s general counsel facing the prospect of liability for duty of care violations due to the company’s material omissions in an SEC filing. Summary and commentary here. PFAS Legislation. Last week, the U.S. House of Representatives passed HR 535 that would impose significant restrictions on the use of PFAS chemicals and heavy clean-up fines for manufacturers. Senator John Barrasso of Wyoming has stated the bill has no chance in the Senate. Joint Venture Governance. The JV structure is a popular and important deal structure for the chemical industry. This article runs interesting comparisons of JV governance against public company governance. Exxon Climate Change Case Ends in a Whimper. Bringing an end to the supposedly groundbreaking case by the New York Attorney General’s office over whether Exxon misled its investors with respect to the potential impact of climate change on its business, in December, the trial court judge ruled against the AG’s office on all counts. Earlier this week, the AG’s office announced it would not appeal. CORPORATE LAW Delaware Continues to Refine MAE Standards In our November 2018 edition, we commented on the special relevance of the laws surrounding material adverse change (MAC) provisions for the chemical industry. With the cyclical nature of some sectors in the industry, questions over MACs can become more complex than in other spaces, as evidenced by the Delaware decision in Hexion Specialty Chems. Inc. v. Huntsman Corp, 965 A.2d 715 (Del. Ch. 2008). In 2018, we then reviewed the landmark decision Akorn, Inc. v. Fresenius Kabi AG, which marked the first time that the Chancery Court upheld a buyer’s use of a MAC clause to terminate a merger agreement. However, the Court’s reasoning in that case suggested that the favorable ruling was based on the particularity of the facts and that the general standard for successfully invoking such a clause remains high. The Court’s recent decision in Channel Medsystems v. Boston Sci. Corp confirms the continuation of that high standard and reaffirms the Delaware Court’s stance that a MAC clause cannot be invoked to alleviate the effects of “buyer’s remorse” or undesirable business decisions. We cover the Channel decision in more detail in this e-update, but in brief, Channel v. Boston Scientific reaffirms that despite the Chancery Court’s decision in Akorn in 2018, the bar for invoking a MAE clause to terminate a merger agreement is still high. Material inaccuracies in the representations and warranties are not enough to trigger a Material Adverse Effect. Rather, the buyer must show that at the time of termination that there is a future expectation of a long-term adverse effect on the earning power of the target business. For more information, contact Layne Smith and Akosua Owusu-Akyaw. Blackrock and ESG Risks In its November 2019 10-K, Scotts Miracle-Gro broke new ground (at least in the chem industry) with a risk factor warning of risks associated with its corporate citizenship and sustainability efforts. The risk factor notes that “There is an increasing focus from certain investors, customers, consumers, employees, and other stakeholders concerning corporate citizenship and sustainability matters” and “we could fail, or be perceived to fail, in our achievement of such initiatives or goals.” It’s easy to see how these risks can have a material impact on companies.  Last year, despite being an early and vocal proponent of corporate responsibility, Blackrock Inc. saw itself receiving criticism from a number of directions for not doing enough, particularly with respect climate change. Perhaps in response, earlier this month, in its annual letter to clients, Blackrock’s CEO announced significant capital reallocation that would lower exposure to fossil fuel companies and move out of thermal coal stocks altogether. That’s all well and good, but it is a stark reminder that companies can face serious headwinds in the capital markets by not fitting into investors’ sustainability goals. For more information, contact Troy Keller.

Firm Highlights

Insights

Minnesota Consumer-Fraud Enforcement: Disclaimers Won’t Cure Deception, and Penalties Can Add Up

Misleading advertising claims can lead to costly consequences. In State of Minnesota ex rel. Ellison v. Wall & Associates, Inc., No. A25-2064, 2026 WL 3118291 (Minn. App. Oct. 19, 2026), the Minnesota Court of Appeals recently affirmed a bench trial verdict against a tax-relief company and two executives for violations of the Minnesota Consumer Fraud Act (“MCFA”) and the Minnesota Deceptive Trade Practices Act (“MDTPA”). The decision, which affirmed a substantial restitution and civil penalty judgment, underscores the broad power of the Minnesota Attorney General to act against deceptive sales practices. The decision also offers practical lessons for businesses seeking to reduce liability risks in consumer-facing communications. Background Wall & Associates (“W&A”), a Virginia-based tax-relief company, marketed assistance to taxpayers seeking relief from outstanding federal and state tax liabilities, often with offers in compromise—agreements to settle tax liabilities for less than the amount owed. In its extensive advertising campaigns, W&A represented that its average client received a 90% reduction in their tax debt, that it was a local company with Minnesota offices, that it provided legal services, and that it would “Solve ALL Tax Problems.” In reality, W&A’s promises bore little resemblance to what many clients received. Most of W&A’s clients saw just a 9.5% reduction in federal tax debt and 1.2% in state tax debt. W&A had no permanent Minnesota offices. And W&A provided neither legal representation nor assistance with filing tax returns—those services required referrals to separate firms for an additional fee. All the while, W&A clients paid upfront and recurring fees, including during periods when W&A did no work on their cases. Minnesota Attorney General Keith Ellison sued W&A, its founder and owner Ernest Kenneth Wall, and its president and CEO Patrick Mark Yates, alleging violations of, among other laws, the MCFA and the MDTPA. Following a 12-day bench trial, the district court determined that W&A violated the MCFA and MDTPA through its false and embellished advertising. The district court also held Wall and Yates individually liable for those violations because they directed, participated in, and acquiesced in the violations. The district court ordered injunctive relief, $2.7 million in restitution (with Wall and Yates jointly and severally liable for $1.3 million), and civil penalties of $786,517 against W&A, $415,500 against Wall, and $207,750 against Yates. The district court also awarded over $2.5 million in attorneys’ fees and costs to the state. W&A, Wall, and Yates appealed to the Minnesota Court of Appeals, which affirmed the district court’s decision on October 19, 2026. Although W&A, Wall, and Yates challenged the judgment on numerous grounds, several highlights of the decision provide important takeaways for consumer-facing businesses. Individual Reliance Is Not Required for Statutory Liability W&A argued that Attorney General Ellison had to prove a causal nexus between each violation of the MCFA and MDTPA and the injury to a particular consumer to establish liability. In W&A’s view, this required proof that each injured consumer had personally relied on W&A’s false representation. The Court of Appeals rejected this argument based on the MCFA’s and MDTPA’s plain language, which requires no proof of actual deception or confusion by consumers. The Court of Appeals finally pointed to the Minnesota Supreme Court’s decision in State v. Minnesota School of Business, Inc., which held that when a defendant’s misrepresentations are directed at and affected “a broad group of consumers, proof of direct individual reliance is not required to establish a causal nexus between MCFA violations and the harm suffered by consumers.” 935 N.W.2d 124, 135 (Minn. 2019). The Court of Appeals affirmed, however, that a causal nexus is necessary to support an award of damages under the MCFA and MDTPA. In making that determination, district courts look to various factors, including whether the misrepresentations were “longstanding, pervasive, and widespread in communications directed to consumers,” whether the seller intended and understood that consumers would rely on the misrepresentations, and whether the information was of a kind on which consumers would typically rely. The Court of Appeals’ decision continues Minnesota School of Business’s broad interpretation of liability under the MCFA and the MDTPA. Coordinated marketing campaigns to a “broad group of consumers” may expose businesses to MCFA and MDTPA liability without customer-by-customer proof of injury. That said, a causal nexus remains an element of an MCFA and MDTPA claim, and businesses involved in litigation should build a clear record at trial and on appeal showing how each of the relevant factors bears on the causal-nexus inquiry. Contractual Disclaimers Are Not an Automatic Defense to a Misleading Pitch W&A next argued that disclaimers in its client contracts prevented consumers from claiming they had been misled by its advertising. Reiterating that individual reliance is not required under the MCFA and MDTPA, the Court of Appeals held that a contractual disclaimer does not necessarily defeat a claim based on a conflicting oral representation. And on the facts of this case, the Court of Appeals agreed with the district court that W&A’s contractual disclaimers were insufficient given the extensive misrepresentations by W&A and the unequal bargaining power between it and its customers. This holding confirms that contractual disclaimers are not a cure-all for misleading advertising or sales practices. Businesses should review the entire customer journey, including pre-contract representations, as those representations may survive a contractual disclaimer to the contrary. And if faced with litigation, businesses should build a strong record, both at trial and on appeal, showing why any disclaimer is effective in context. The State Has Broad Authority to Seek Restitution W&A also challenged Attorney General Ellison’s authority to seek restitution under the state’s parens patriae authority to protect residents’ collective interests, arguing that injury to only 228 Minnesotans did not affect a sufficiently substantial segment of the population. The Court of Appeals rejected a simple headcount approach, instead explaining that the state had a legitimate interest in protecting residents’ economic well-being as a whole. In any event, the Court of Appeals held that if restitution was not appropriate under the state’s parens patriae authority, then it would still be appropriate under the Attorney General’s enforcement powers under Minn. Stat. § 8.31. The decision reinforces that the broader and more sustained the deceptive advertising, the stronger the case for restitution to protect Minnesotans’ economic interests. Civil Penalties Accrue Per Violation, Not Per Defendant The Court of Appeals finally rejected W&A’s claim that the Attorney General’s enforcement powers under Minn. Stat. § 8.31 permit only civil penalties of up to $25,000 for each defendant. Rather, the Court of Appeals explained that penalties are limited to $25,000 per violation. Multiple violations can therefore produce substantially greater penalties. The Court of Appeals also rejected the argument that restitution made penalties unnecessary: repaying consumers does not eliminate the need to address gains from deceptive conduct and deter future violations. Final Takeaways Align every consumer-facing communication. Broad and extensive marketing campaigns can expose businesses to stronger enforcement standards under the MCFA and MDTPA, making it critical that consumer communications remain accurate and consistent from the first advertisement through the final sale. Plan for layered enforcement exposure. Penalties under the MCFA and MDTPA can add up quickly: W&A, Wall, and Yates ultimately faced more than $6 million in civil penalties, restitution, and attorneys’ fees. The decision continues a line of Minnesota cases recognizing the Attorney General’s broad consumer-protection authority. Details matter. Although the Attorney General’s enforcement power is broad, it is not boundless. As the Court of Appeals explained, issues of causation, the effectiveness of contractual disclaimers, and the availability of restitution and civil penalties all turn on the specific facts of the case. Effective advocacy at trial and on appeal is critical to developing the facts relevant to liability and damages.